Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 4:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Xalatan Clear all
Completed Phase 4 Interventional Accepts healthy volunteers

Comparison of Istalol™ 0.5% QD (Timolol Maleate/Sorbitol Complex, ISTA Pharmaceutical) to Brimonidine Tartrate 0.1% BID as Adjunctive Therapy to Latanoprost 0.005% in Adults With Ocular Hypertension (OHT) or Open-Angle Glaucoma (OAG)

NCT00698945
View directory record Official record
Conditions
Ocular Hypertension, Open-Angle Glaucoma
Interventions
Istalol and Optive, Alphagan
Drug
Lead sponsor
Bp Consulting, Inc
Network
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Petaluma, California
Source: ClinicalTrials.gov public record
Updated Dec 3, 2008 · Synced Sep 25, 2026, 4:35 PM EDT
Completed Phase 3 Interventional Results available

Double-masked Study of PG324 Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension

NCT02674854
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
PG324 Ophthalmic Solution 0.02%/0.005%, Netarsudil (AR-13324) ophthalmic solution 0.02%, Latanoprost ophthalmic solution 0.005%
Drug
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Bedminster, New Jersey
Source: ClinicalTrials.gov public record
Updated May 20, 2019 · Synced Sep 25, 2026, 4:35 PM EDT
Completed Phase 2 Interventional Results available

Study to Assess the Efficacy, Safety and Tolerability of AKB-9778 Ophthalmic Solution as and Adjunct to Latanoprost in Patients With Ocular Hypertension or Open Angle Glaucoma

NCT04405245
View directory record Official record
Conditions
Ocular Hypertension, Primary Open Angle Glaucoma
Interventions
Latanoprost ophthalmic solution, AKB-9778 4%, Placebo
Drug
Lead sponsor
EyePoint Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
21
States / cities
Inglewood, California • Mission Hills, California • Newport Beach, California + 18 more
Source: ClinicalTrials.gov public record
Updated May 24, 2023 · Synced Sep 25, 2026, 4:35 PM EDT
Not listed Not applicable Interventional

Comparison of Efficacy of Two Groups of Glaucoma Drops (Xalatan vs.Cosopt) in Reducing Eye Pressure Following Laser (SLT)Treatment in the Management of Glaucoma.

NCT00440336
View directory record Official record
Conditions
Open Angle Glaucoma
Interventions
Cosopt, Xalatan
Drug
Lead sponsor
Advanced Glaucoma Specialists
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Reading, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 28, 2007 · Synced Sep 25, 2026, 4:35 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Trial of NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension

NCT04445519
View directory record Official record
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
NCX 470 0.065% (initial phase of trial), Latanoprost 0.005% (initial phase of trial), NCX 470 0.1% (initial phase of trial), NCX 470 0.1% (remainder of trial), Latanoprost 0.005% (remainder of trial)
Drug
Lead sponsor
Nicox Ophthalmics, Inc.
Industry
Eligibility
18 Years to 84 Years
Enrollment
691 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Jun 23, 2025 · Synced Sep 25, 2026, 4:35 PM EDT
Completed Not applicable Interventional Results available

The Diurnal and Nocturnal Effect of Pilocarpine on Intraocular Pressure and Ocular Perfusion Pressure

NCT02754570
View directory record Official record
Conditions
Glaucoma, Open-angle, Hypertension, Ocular
Interventions
Pilocarpine
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 89 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 6, 2019 · Synced Sep 25, 2026, 4:35 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Intraocular Pressure (IOP) Lowering Efficacy of Transdermal Latanoprost Therapy

NCT01426464
View directory record Official record
Conditions
Glaucoma
Interventions
0.005% Latanoprost dosed once.
Drug
Lead sponsor
Nanduri, Padma, M.D., FACS
Individual
Eligibility
21 Years and older
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Visalia, California
Source: ClinicalTrials.gov public record
Updated Aug 30, 2011 · Synced Sep 25, 2026, 4:35 PM EDT
Completed Phase 1Phase 2 Interventional

Efficacy, Tolerability and Safety of RKI983 (0.05% & 0.10%) vs Xalatan in Patients With POAG or Ocular Hypertension

NCT00846989
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
RKI983A, Latanoprost
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
29
States / cities
Artesia, California • Inglewood, California • La Jolla, California + 25 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced Sep 25, 2026, 4:35 PM EDT
Completed No phase listed Observational

Relationship Between Eye Pressure and Ganglion Cell Function in Eyes Receiving Latanoprost Versus Placebo

NCT01042665
View directory record Official record
Conditions
Glaucoma
Interventions
latanoprost 0.005%, Placebo
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 85 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Palm Beach Gardens, Florida
Source: ClinicalTrials.gov public record
Updated Mar 27, 2014 · Synced Sep 25, 2026, 4:35 PM EDT
Completed Phase 2 Interventional Results available

Study Comparing the Safety and Efficacy of BOL-303259-X to Latanoprost in Subjects With Glaucoma or Ocular Hypertension

NCT01223378
View directory record Official record
Conditions
Intraocular Pressure
Interventions
BOL-303259-X, Latanoprost
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jul 23, 2018 · Synced Sep 25, 2026, 4:35 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of PF-04217329 in Patients With Glaucoma or Elevated Eye Pressure.

NCT00572455
View directory record Official record
Conditions
Primary Open-Angle Glaucoma, Ocular Hypertension
Interventions
PF-04217329 - Lowest Dose, PF-04217329 - Low Dose, PF-04217329 - Middle Dose, PF-04217329 - High Middle Dose, PF-04217329 - High Dose, PF-4217329 - Highest Dose, PF-04217329 - Vehicle, Latanoprost Vehicle, Latanoprost 0.005%
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
23
States / cities
Artesia, California • Newport Beach, California • Petaluma, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2021 · Synced Sep 25, 2026, 4:35 PM EDT
Not listed Not applicable Interventional

Effects of Xal-Ease on Patient Compliance With Xalatan

NCT00573638
View directory record Official record
Conditions
Glaucoma
Interventions
Xal-Ease device to be used with Xalatan eye drops
Device
Lead sponsor
Augusta University
Other
Eligibility
40 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 7, 2008 · Synced Sep 25, 2026, 4:35 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Glaucoma Biomarkers

NCT01677507
View directory record Official record
Conditions
Glaucoma, Healthy
Interventions
Variation in eye pressure response to timolol and latanoprost treatment
Drug
Lead sponsor
University of Michigan
Other
Eligibility
40 Years and older
Enrollment
135 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
3
States / cities
Ann Arbor, Michigan • Rochester, Minnesota • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 12, 2017 · Synced Sep 25, 2026, 4:35 PM EDT
Completed Phase 4 Interventional Results available

How Similar Are Changes to the Surface of the Eye When Two Different Glaucoma Eye Drops Are Used?

NCT00798694
View directory record Official record
Conditions
Glaucoma
Interventions
Xalatan, Travatan Z
Drug
Lead sponsor
Wills Eye
Other
Eligibility
21 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 11, 2018 · Synced Sep 25, 2026, 4:35 PM EDT
Completed No phase listed Observational Results available

Safety and Efficacy Study of Bimatoprost, Latanoprost, and Travoprost in Patients With Elevated Intraocular Pressure (IOP) and Open-angle Glaucoma (OAG)

NCT00716742
View directory record Official record
Conditions
Open-Angle Glaucoma, Ocular Hypertension
Interventions
bimatoprost 0.03%, latanoprost 0.005%, and travoprost 0.004%
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
1,099 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Murfreesboro, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 5, 2012 · Synced Sep 25, 2026, 4:35 PM EDT
Suspended Phase 1Phase 2 Interventional

Safety and Efficacy Study of JV-GL1 in Patients With Open-Angle Glaucoma or Ocular Hypertension

NCT04761705
View directory record Official record
Conditions
Ocular Hypertension, Open Angle Glaucoma
Interventions
JV-GL1, Latanoprost 0.005% Ophthalmic Solution
Drug
Lead sponsor
JeniVision, Inc.
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated May 9, 2024 · Synced Sep 25, 2026, 4:35 PM EDT
Completed Phase 2 Interventional

A Dose Evaluation Study of the Effect of Plug Placement on the Efficacy and Safety of the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open-Angle Glaucoma

NCT01481077
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension (OH)
Interventions
Latanoprost-PPDS
Drug
Lead sponsor
Mati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
11
States / cities
Springdale, Arkansas • Denver, Colorado • Danbury, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2013 · Synced Sep 25, 2026, 4:35 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Study of Corneal Biomechanics in Glaucoma Patients Using Brillouin Microscopy

NCT06993597
View directory record Official record
Conditions
Glaucoma
Interventions
Prostaglandin Analogue -Containing IOP-Lowering Therapy, Beta Blocker, Brillouin Microscopy
Drug · Device
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 25, 2026, 4:35 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

The International Collaborative Exfoliation Syndrome Treatment Study

NCT00804115
View directory record Official record
Conditions
Exfoliation Syndrome, Glaucoma, Ocular Hypertension
Interventions
Latanoprost with Pilocarpine vs Timolol or Cosopt
Drug
Lead sponsor
The New York Eye & Ear Infirmary
Other
Eligibility
50 Years to 80 Years
Enrollment
277 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 7, 2008 · Synced Sep 25, 2026, 4:35 PM EDT
Completed No phase listed Observational

Improved Efficacy of Selective Laser Trabeculoplasty With the Addition of Rocklatan Post-treatment vs Artificial Tears Post-treatment

NCT06819046
View directory record Official record
Conditions
Glaucoma
Interventions
Rocklatan, Systane Ultra
Drug
Lead sponsor
Colorado Ophthalmology Associates PC
Other
Eligibility
18 Years and older
Enrollment
70 participants
Timeline
2025
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Sep 25, 2026, 4:35 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of Catioprost® (Unpreserved Latanoprost 0.005% Emulsion) Compared to Travatan Z® to Treat Glaucoma and Ocular Surface Disease

NCT01254370
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension, Ocular Surface Disease
Interventions
Latanoprost, Travatan Z
Drug
Lead sponsor
Santen SAS
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 5, 2016 · Synced Sep 25, 2026, 4:35 PM EDT
Not listed Early Phase 1 Interventional Accepts healthy volunteers

Short-term Effect of Rho-kinase Inhibitor on Retinal Circulation

NCT04234932
View directory record Official record
Conditions
Glaucoma, Open-Angle
Interventions
Netarsudil Ophthalmic
Drug
Lead sponsor
University of the Incarnate Word
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 13, 2020 · Synced Sep 25, 2026, 4:35 PM EDT